Get the Stockscreener App
23.35
0.55%
-0.13
After Hours:
23.35
Pacira Biosciences Inc stock is traded at $23.35, with a volume of 852.38K.
It is down -0.55% in the last 24 hours and down -6.15% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$23.48
Open:
$23.5
24h Volume:
852.38K
Relative Volume:
1.24
Market Cap:
$918.77M
Revenue:
$734.86M
Net Income/Loss:
$5.14M
P/E Ratio:
186.80
EPS:
0.125
Net Cash Flow:
$132.71M
1W Performance:
+3.14%
1M Performance:
-6.15%
6M Performance:
+1.30%
1Y Performance:
-10.43%
1-Day Range:
$23.24
$23.74
1-Week Range:
$21.92
$23.86
52-Week Range:
$18.80
$27.64
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
23.35 | 923.89M | 734.86M | 5.14M | 132.71M | 0.125 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Equal Weight |
| Nov-17-25 | Initiated | H.C. Wainwright | Buy |
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
Pacira shareholders lobbied by hedge fund board nominees - MSN
PCRX Stock Chart | PACIRA BIOSCIENCES INC (NASDAQ:PCRX) - ChartMill
[DFAN14A] Pacira BioSciences, Inc. SEC Filing - Stock Titan
DOMA Perpetual Capital Issues a Press Release to Pacira BioSciences Shareholders - marketscreener.com
Doma Perpetual urges Pacira BioSciences shareholders to judge sale price adequacy - marketscreener.com
Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy - TradingView
A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC - PR Newswire
DOMA Perpetual Issues a Press Release to Shareholders of Pacira BioSciences - marketscreener.com
PCRX: DOMA Capital Advocates for Change in Pacira BioSciences Bo - GuruFocus
DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences - Nasdaq
Pacira Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Pacira BioSciences Issues Investor Presentation for Shareholders - marketscreener.com
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders - The Manila Times
Pacira BioSciences Files Investor Presentation Highlighting - GlobeNewswire
Pacira Q1 earnings miss estimates on higher costs, revenues rise y/y - MSN
Do options traders know something about Pacira BioSciences stock we don't? - MSN
Pacira BioSciences: Exparel Still Supports My Original Bull Case (NASDAQ:PCRX) - Seeking Alpha
Pacira BioSciences, Inc.Common Stock (NQ: PCRX - The Chronicle-Journal
(PCRX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Pacira BioSciences stock (US6951271005): Activist investor DOMA nominates three board directors - AD HOC NEWS
UBS Group AG Has $14.46 Million Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciencesAlong with its Definitive Proxy Statement & WHITE Proxy CardUrging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates - Sahm
DOMA Perpetual nominates three directors to Pacira board By Investing.com - Investing.com India
Concerns Rise Over Pacira BioSciences' (PCRX) Board Management S - GuruFocus
Pacira BioSciences' (NASDAQ:PCRX) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
DOMA Perpetual nominates three directors to Pacira board - Investing.com UK
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences - Yahoo Finance
Vanguard Group Inc. Sells 384,612 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
DOMA Perpetual Capital Solicits Proxies from Shareholders of Pacira BioSciences - marketscreener.com
Pacira BioSciences sends letter to stockholders reiterating superior qualifications of its board nominees - marketscreener.com
Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees - TradingView
Activist DOMA (PCRX) Seeks CEO Removal, Board Seats; Pushes Sale Vote - Stock Titan
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees - GlobeNewswire
HC Wainwright Expects Lower Earnings for Pacira BioSciences - MarketBeat
Pacira Q1 2026 slides: EXPAREL growth accelerates, margins compress By Investing.com - Investing.com Australia
Earnings call transcript: Pacira BioSciences Q1 2026 earnings exceed forecasts - Investing.com UK
Earnings call transcript: Pacira BioSciences Q1 2026 earnings exceed forecasts By Investing.com - Investing.com Australia
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
10 new Pacira hires get stock options and restricted units - Stock Titan
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pacira BioSciences Reports Strong Q1 2026 Results and Highlights Success of 5x30 Strategy, Urges Stockholders to Vote "FOR" Board Nominees - Quiver Quantitative
Pacira BioSciences Mails Letter to Stockholders - The Manila Times
PACIRA BIOSCIENCES INC (NASDAQ:PCRX): A Value Stock Candidate with Margin of Safety - ChartMill
Contact - FinancialContent
MSN Money - MSN
How Pacira’s Q1 2026 Results, EXPAREL Data and Proxy Battle May Impact Pacira BioSciences (PCRX) Investors - Sahm
Price-Driven Insight from (PCRX) for Rule-Based Strategy - Stock Traders Daily
Assessing Pacira BioSciences (PCRX) Valuation After Earnings Update And New EXPAREL Real World Data - Yahoo Finance
Pacira Biosciences Q1 Non-GAAP Earnings Fall, Revenue Rises; 2026 Sales Forecast Maintained - Moomoo
Universal Beteiligungs und Servicegesellschaft mbH Boosts Stock Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):